These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22483068)

  • 1. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes.
    Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ
    Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068
    [No Abstract]   [Full Text] [Related]  

  • 2. Neutrophilic panniculitis associated with myelodysplastic syndrome with abnormal nuclear forms.
    Becherer K; Golda N; Feldman M; Diaz-Arias A; Caldwell C
    J Cutan Pathol; 2009 Sep; 36(9):1024-6. PubMed ID: 19674208
    [No Abstract]   [Full Text] [Related]  

  • 3. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 4. Strongly suspicious hemolysis caused by azacitidine in a myelodysplastic syndrome patient.
    Ichikawa K; Aritaka N; Ogura K; Komatsu N; Hirano T
    Geriatr Gerontol Int; 2014 Oct; 14(4):1006-7. PubMed ID: 25327907
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
    Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G
    Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879
    [No Abstract]   [Full Text] [Related]  

  • 6. Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine.
    Infante MS; Muñoz C; Heras C; Foncillas MA; González I; Lucea I; Echavarria E; Aramendi T; Hernández JA
    Eur J Dermatol; 2015; 25(6):622-3. PubMed ID: 26552844
    [No Abstract]   [Full Text] [Related]  

  • 7. Decitabine.
    Gore SD; Jones C; Kirkpatrick P
    Nat Rev Drug Discov; 2006 Nov; 5(11):891-2. PubMed ID: 17117522
    [No Abstract]   [Full Text] [Related]  

  • 8. Azacitidine and the beginnings of therapeutic epigenetic modulation.
    O'Dwyer K; Maslak P
    Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome.
    Tseng E; Alhusayen R; Sade S; Buckstein R; Prica A
    Br J Haematol; 2015 May; 169(4):461. PubMed ID: 25765235
    [No Abstract]   [Full Text] [Related]  

  • 10. Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.
    Radsak M; Platzbecker U; Schmidt CS; Hofmann WK; Nolte F
    Eur J Haematol; 2017 Aug; 99(2):112-118. PubMed ID: 28321924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome.
    Makita S; Munakata W; Watabe D; Maeshima AM; Taniguchi H; Toyoda K; Yamauchi N; Fukuhara S; Maruyama D; Kobayashi Y; Tobinai K
    J Int Med Res; 2017 Apr; 45(2):886-893. PubMed ID: 28415946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome.
    Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Ueno D; Yamasaki T; Itoh T; Yokozaki H; Katayama Y
    Eur J Haematol; 2014 Apr; 92(4):362-4. PubMed ID: 24341928
    [No Abstract]   [Full Text] [Related]  

  • 13. Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome.
    Adams CD; Szumita PM; Baroletti SA; Lilly CM
    Pharmacotherapy; 2005 May; 25(5):765-8. PubMed ID: 15899739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eosinophilic pneumonia associated with azacitidine in a patient with myelodysplastic syndrome.
    Nair GB; Charles M; Ogden L; Spiegler P
    Respir Care; 2012 Apr; 57(4):631-3. PubMed ID: 22005027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atraumatic splenic rupture in patients with myelodysplastic syndromes: report of a case occurred during treatment with 5-azacitidine and review of the literature.
    Forghieri F; Morselli M; Leonardi G; Potenza L; Bonacorsi G; Coluccio V; Paolini A; Maccaferri M; Colaci E; Fantuzzi V; Bigliardi S; Zaldini P; Riva G; Barozzi P; Leonardi L; Rossi A; Marasca R; Narni F; Luppi M
    Leuk Res; 2012 Mar; 36(3):e52-6. PubMed ID: 22172466
    [No Abstract]   [Full Text] [Related]  

  • 16. Interstitial lung disease associated with azacitidine use: a case report.
    Sekhri A; Palaniswamy C; Kurmayagari K; Kalra A; Selvaraj DR
    Am J Ther; 2012 Mar; 19(2):e98-e100. PubMed ID: 20634671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous adverse events induced by azacitidine in myelodysplastic syndrome patients: Case reports and a lesson from published work review.
    Shimoda-Komatsu Y; Mizukawa Y; Takayama N; Ohyama M
    J Dermatol; 2020 Apr; 47(4):363-368. PubMed ID: 32056290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study.
    Stamatoullas A; Rezine I; Mareschal S; Ménard AL; Lanic H; David M; Daliphard S; Penther D; Lemasle E; Cassuto O; Lenain P; Contentin N; Lepretre S; Jardin F; Bastard C; Tilly H
    Leuk Lymphoma; 2016; 57(6):1491-3. PubMed ID: 26430832
    [No Abstract]   [Full Text] [Related]  

  • 19. Hematology: Azacitidine improves survival in myelodysplastic syndromes.
    Rose MG
    Nat Rev Clin Oncol; 2009 Sep; 6(9):502-3. PubMed ID: 19707240
    [No Abstract]   [Full Text] [Related]  

  • 20. 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.
    Breccia M; Cannella L; Santopietro M; Loglisci G; Federico V; Salaroli A; Nanni M; Mancini M; Alimena G
    Leukemia; 2011 Apr; 25(4):736-7. PubMed ID: 21293489
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.